TriSalus Life Sciences announced the launch of the TriNav FLX Infusion System, the latest addition to its TriNav Portfolio. The TriNav FLX system introduces enhanced trackability, featuring twice the length of more flexible material at the distal end, which allows for easier navigation through tortuous vessels.
This advancement is particularly beneficial for procedures requiring precise control and flexibility due to challenging peripheral vascular anatomy. The TriNav FLX Infusion System retains the core benefits of the Pressure-Enabled Drug Delivery (PEDD) technology found in existing products.
Importantly, TriNav FLX is eligible for reimbursement under HCPCS Code C8004 for simulation or mapping procedures, as well as C9797 for treatment procedures. This dual coverage enables clinicians to use TriNav FLX for both planning and delivery in radioembolization, supporting greater precision and continuity of care.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.